Comprehensive pharmacologic therapy for treatment of obesity

Abstract

The comprehensive pharmacologic therapy for treatment of obesity is a procedure which involves the administration of a desired therapeutic range of Diethylpropion and / or Phentermine in combination with a SSRI medication and nutritional supplementation for brief and long durations which may be 12 months or more. The preferred procedure involves the administration of drugs in combination which are identified as: Citalopram (Celexa) and Phentermine; Citalopram (Celexa) and Diethylpropion; Citalopram (Celexa), Phentermine, and Diethylpropion. In addition nutritional supplementation such as a multivitamin, 5-Hydroxytryptophan, vitamin B6, vitamin C, Tyrosine, Calcium, and Lysine may be used to enhance the performance of the weight loss treatment program.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS [0001] This application is a continuation of U.S. patent application Ser. No. 11 / 157,198, filed on Jun. 20, 2005, which is a continuation of U.S. patent application Ser. No. 10 / 715,912, filed on Nov. 18, 2003, which is a continuation of U.S. patent application Ser. No. 09 / 942,188, filed on Aug. 29, 2001, now U.S. Pat. No. 6,660,777, which is a division of U.S. patent application Ser. No. 09 / 412,701, filed on Oct. 4, 1999, now U.S. Pat. No. 6,403,657, which patent applications are hereby incorporated-by-reference herein.BACKGROUND OF THE INVENTION [0002] Research has identified that long term use of medications for treatment of obesity in patients has resulted in many problems. The two most significant problems encountered by patients using medications to assist in weight loss, assuming the absence of irreversible side effects from the medications, are that: [0003] The medications stop working during therapy where at least 40% to 50% of patient...

AI Technical Summary

Benefits of technology

[0011] The invention embodies the use of Phentermine and / or Diethylpropion with an SSRI medication, Citalopram. The SSRI medication is used in an “effective therapeutic range” to provide optimal results. The treatment enables individuals to have a much higher expectation of weight loss to achieve a desired weight than the previous known treatments. The method of weight loss enables individuals to lose weight optimally and safely. With treatment, as individuals lose weight other diseases or illnesses caused by or associated with weight problems get markedly better or resolve completely such as type II diabetes, hypertension, hypercholesterolemia, orthopedic problems, depression, anxiety, panic attacks, migraine headaches, PMS, chronic pain states, fibromyalgia, insomnia, sleep apnea, impulsivity, obsessive compulsive disorder, and myoclonus. Duration of treatment may be long term, or for life if needed, to reduce weight and maintain weight loss as desired by an individual.

[0012] A principal object of the present invention is the provision of a comprehensive pharmacologic therapy for treatment of obesity of relatively simple and inexpensive design which fulfills the intended purpose of appetite suppression to enable weight loss without fear of injury to persons.

[0013] Another principal object of the present invention is the provision of a comprehensive pharmacologic therapy for treatment of obesity which is easy for patients to initiate and continue to effectuate weight loss.

Problems solved by technology

Research has identified that long term use of medications for treatment of obesity in patients has resulted in many problems.

In the past long term treatment, defined as treatment longer than 3 months to many years, with drugs has been a problem due to long term safety issues including, medication intolerability by the patient, medication side effects and most important ineffectiveness of the drugs or the cessation of benefit of the drugs which in turn causes the patient to fall out of appetite suppression and terminate weight loss.

The potential for patients to obtain goal weight loss under the process of U.S. Pat. No. 5,795,895 is low, and the failure of the drugs to provide a desired level of performance is at the heart of the problem.

A single dosing schedule of SSRI medication is not optimal for a desired level of weight loss performance.

Individuals frequently fail to lose a desired amount of weight when alternative doses of medication are unavailable.

Second, patients receiving treatment for weight loss through the use of medication frequently experience complications such as a cessation of performance of the medication due to a “nutritional deficiency”.

Frequently it is difficult to predict which patients are likely to experience unacceptable performance of weight loss medication due to “nutritional deficiencies” associated with calorie deficit's.

It is also problematic to predict the outcome of medication treatment upon individuals receiving Norepinephrine medications such as Phentermine and / or Diethylpropion.

These medications have unique chemical properties making the outcome of treatment of patients uncertain.

In addition not all medications function to assist in weight loss.